NL194389C - Werkwijze voor het bereiden van een vaste dispersie van een farmaceutisch actief middel dat een lage oplosbaarheid in water heeft, in een vaste matrix van een in water oplosbaar polyalkyleenglycol als drager. - Google Patents

Werkwijze voor het bereiden van een vaste dispersie van een farmaceutisch actief middel dat een lage oplosbaarheid in water heeft, in een vaste matrix van een in water oplosbaar polyalkyleenglycol als drager. Download PDF

Info

Publication number
NL194389C
NL194389C NL8501578A NL8501578A NL194389C NL 194389 C NL194389 C NL 194389C NL 8501578 A NL8501578 A NL 8501578A NL 8501578 A NL8501578 A NL 8501578A NL 194389 C NL194389 C NL 194389C
Authority
NL
Netherlands
Prior art keywords
active agent
isradipine
carrier
solid
solid dispersion
Prior art date
Application number
NL8501578A
Other languages
English (en)
Dutch (nl)
Other versions
NL8501578A (nl
NL194389B (nl
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NL8501578A publication Critical patent/NL8501578A/nl
Publication of NL194389B publication Critical patent/NL194389B/xx
Application granted granted Critical
Publication of NL194389C publication Critical patent/NL194389C/nl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
NL8501578A 1984-06-14 1985-05-31 Werkwijze voor het bereiden van een vaste dispersie van een farmaceutisch actief middel dat een lage oplosbaarheid in water heeft, in een vaste matrix van een in water oplosbaar polyalkyleenglycol als drager. NL194389C (nl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE3422083 1984-06-14
DE3422083 1984-06-14
DE3442566 1984-11-22
DE3442566 1984-11-22

Publications (3)

Publication Number Publication Date
NL8501578A NL8501578A (nl) 1986-01-02
NL194389B NL194389B (nl) 2001-11-01
NL194389C true NL194389C (nl) 2002-03-04

Family

ID=25822108

Family Applications (1)

Application Number Title Priority Date Filing Date
NL8501578A NL194389C (nl) 1984-06-14 1985-05-31 Werkwijze voor het bereiden van een vaste dispersie van een farmaceutisch actief middel dat een lage oplosbaarheid in water heeft, in een vaste matrix van een in water oplosbaar polyalkyleenglycol als drager.

Country Status (21)

Country Link
AT (1) AT391806B (pt)
AU (2) AU587190B2 (pt)
BE (1) BE902626A (pt)
CA (1) CA1264441A (pt)
CY (1) CY1635A (pt)
DE (1) DE3520184C2 (pt)
DK (1) DK167649B1 (pt)
ES (1) ES8702141A1 (pt)
FR (1) FR2565822B1 (pt)
GB (3) GB2160100B (pt)
GR (1) GR851430B (pt)
HK (1) HK25192A (pt)
HU (1) HU198844B (pt)
IE (1) IE58834B1 (pt)
IL (1) IL75490A0 (pt)
IT (1) IT1200080B (pt)
LU (1) LU85946A1 (pt)
NL (1) NL194389C (pt)
NZ (1) NZ212390A (pt)
PT (1) PT80635B (pt)
SE (1) SE504583C2 (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1187751B (it) * 1985-10-15 1987-12-23 Eurand Spa Procedimento per la preparazione di formulazioni solidi di nifedipina ad elevata biodisponibilita' e ad effetto prolungato e formulazioni cosi' ottenute
US4816263A (en) * 1987-10-02 1989-03-28 Alza Corporation Dosage form for treating cardiovascular diseases comprising isradipine
WO1989009066A1 (en) * 1988-03-24 1989-10-05 Bukh Meditec A/S Controlled release composition
GR1000270B (el) * 1988-09-30 1992-05-12 Alza Corp Μορφη δοσολογιας για θεραπεια καρδιαγγειακων ασθενειων.
DK469989D0 (da) * 1989-09-22 1989-09-22 Bukh Meditec Farmaceutisk praeparat
MX9300110A (es) * 1992-01-13 1994-07-29 Gerhard Gergely Preparacion farmaceutica en la forma de una tableta de efervescencia o de desintegracion o de un granulado de tipo instanteneo y procedimiento para su preparacion.
DE4201179A1 (de) * 1992-01-17 1993-07-22 Alfatec Pharma Gmbh Wirkstoff(e) enthaltendes granulat oder pellet mit einem geruest aus hydrophilen makromolekuelen und verfahren zu seiner herstellung
US5773025A (en) 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
US6726930B1 (en) 1993-09-09 2004-04-27 Penwest Pharmaceuticals Co. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5455046A (en) * 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
GB2281697A (en) * 1993-09-14 1995-03-15 Euro Celtique Sa Laxative compositions in capsules
ES2322405T3 (es) 1996-07-08 2009-06-19 Penwest Pharmaceuticals Co. Matriz de liberacion controlada para farmacos insolubles en dosis elevadas.
DE19710009A1 (de) * 1997-03-12 1998-09-24 Knoll Ag Mehrphasige wirkstoffhaltige Zubereitungsformen
US6056977A (en) * 1997-10-15 2000-05-02 Edward Mendell Co., Inc. Once-a-day controlled release sulfonylurea formulation
US6787157B1 (en) 1998-03-10 2004-09-07 Abbott Laboratories Multiphase active ingredient-containing formulations
EP1189599A2 (en) * 1999-06-11 2002-03-27 Eli Lilly And Company Pharmaceutical materials and methods for their preparation and use
US7001892B1 (en) 1999-06-11 2006-02-21 Purdue Research Foundation Pharmaceutical materials and methods for their preparation and use
JP3462490B2 (ja) * 1999-08-04 2003-11-05 山之内製薬株式会社 安定な経口用医薬組成物
AU762291B2 (en) 1999-09-30 2003-06-19 Penwest Pharmaceutical Co. Sustained release matrix systems for highly soluble drugs
CA2434542A1 (en) * 2001-02-13 2002-08-22 Anne Juppo Novel modified release formulation
US7135436B2 (en) 2003-05-05 2006-11-14 J.F. Daley International, Ltd. Solid algicide, preparation and usage in recirculating water
EP1690528A1 (de) 2005-02-11 2006-08-16 Abbott GmbH & Co. KG Herstellung von Dosierungsformen mit einer festen Dispersion eines mikrokristallinen Wirkstoffs
US8399007B2 (en) 2006-12-05 2013-03-19 Landec Corporation Method for formulating a controlled-release pharmaceutical formulation
EP2500015A1 (en) 2006-12-05 2012-09-19 Landec Corporation Delivery of drugs
US8114883B2 (en) 2007-12-04 2012-02-14 Landec Corporation Polymer formulations for delivery of bioactive materials
BRPI0917358A2 (pt) 2008-08-20 2015-11-17 Univ Texas formulação farmacêutica de liberação controlada e método.

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1617362A1 (de) * 1967-11-17 1971-03-25 Beiersdorf Ag Verfahren zur Herstellung von Arzneimitteln mit verzoegerter Wirkstoffabgabe in Form von Kapseln
DE2400819C2 (de) * 1974-01-09 1982-04-22 Bayer Ag, 5090 Leverkusen Verfahren zur Herstellung fester Zubereitungen von schwerlöslichen Arzneimittelwirkstoffen in feinster Verteilung
DE2546577B2 (de) * 1975-10-17 1981-04-02 Sandoz-Patent-GmbH, 7850 Lörrach Feste Stoffe aus Polyvinylpyrrolidon und Ergotalkaloiden
GB1504553A (en) * 1975-11-17 1978-03-22 Sandoz Ltd Tablet formulations
GB1579818A (en) * 1977-06-07 1980-11-26 Yamanouchi Pharma Co Ltd Nifedipine-containing solid preparation composition
DK149855C (da) * 1977-06-20 1987-04-21 Sandoz Ag Analogifremgangsmaade til fremstilling af 1,4-dihydropyridinderivater
CH639659A5 (de) * 1978-12-18 1983-11-30 Sandoz Ag Neue 1,4-dihydropyridinderivate, deren herstellung und verwendung.
EP0001247A1 (en) * 1977-09-14 1979-04-04 Kanebo, Ltd. Pharmaceutical preparation containing nifedipine and a method for producing the same.
CH642259A5 (de) * 1978-12-21 1984-04-13 Sandoz Ag Galenische zubereitungen fuer orale applikation von ergotalkaloiden.
DE2904310A1 (de) * 1979-02-05 1980-08-07 Boehringer Mannheim Gmbh Formlinge mit retardierter wirkstofffreisetzung und verfahren zu deren herstellung
JPS56115726A (en) * 1980-02-20 1981-09-11 Kaken Pharmaceut Co Ltd Pharmaceutical containing nifedipine
DE3033919A1 (de) * 1980-09-09 1982-04-22 Bayer Ag, 5090 Leverkusen Feste arzneizubereitungen enthaltend nifedipin und verfahren zu ihrer herstellung
US4442112A (en) * 1981-09-02 1984-04-10 Sandoz Ltd. Dihydropyridine derivatives useful in treating vascular headaches
EP0078430B2 (de) * 1981-10-29 1993-02-10 Bayer Ag Verfahren zur Herstellung von festen, schnellfreisetzenden Arzneizubereitungen mit Dihydropyridinen
CA1208558A (en) * 1982-10-07 1986-07-29 Kazuo Kigasawa Soft buccal
DE3318649A1 (de) * 1983-05-21 1984-11-22 Bayer Ag, 5090 Leverkusen Zweiphasenformulierung

Also Published As

Publication number Publication date
LU85946A1 (fr) 1986-01-24
FR2565822B1 (fr) 1989-02-17
SE504583C2 (sv) 1997-03-10
SE8502950D0 (sv) 1985-06-13
IE851460L (en) 1985-12-14
DK167649B1 (da) 1993-12-06
DK264785A (da) 1985-12-15
IL75490A0 (en) 1985-10-31
AT391806B (de) 1990-12-10
CY1635A (en) 1992-11-06
GB8727056D0 (en) 1987-12-23
IE58834B1 (en) 1993-11-17
GR851430B (pt) 1985-11-25
IT1200080B (it) 1989-01-05
NL8501578A (nl) 1986-01-02
GB2196851A (en) 1988-05-11
SE8502950L (sv) 1985-12-15
AU4348685A (en) 1985-12-19
PT80635A (en) 1985-07-01
GB2196852A (en) 1988-05-11
NZ212390A (en) 1992-02-25
GB2196852B (en) 1989-05-17
GB2160100A (en) 1985-12-18
DK264785D0 (da) 1985-06-12
DE3520184C2 (de) 1997-03-13
GB2160100B (en) 1989-06-01
GB2196851B (en) 1989-06-07
DE3520184A1 (de) 1985-12-19
ES544075A0 (es) 1987-01-01
ES8702141A1 (es) 1987-01-01
GB8727055D0 (en) 1987-12-23
PT80635B (pt) 1987-10-20
GB8514855D0 (en) 1985-07-17
NL194389B (nl) 2001-11-01
BE902626A (fr) 1985-12-10
CA1264441A (en) 1990-01-16
HK25192A (en) 1992-04-10
HUT40918A (en) 1987-03-30
AU4454389A (en) 1990-03-22
IT8548210A0 (it) 1985-06-13
FR2565822A1 (fr) 1985-12-20
AU587190B2 (en) 1989-08-10
ATA174885A (de) 1990-06-15
HU198844B (en) 1989-12-28

Similar Documents

Publication Publication Date Title
NL194389C (nl) Werkwijze voor het bereiden van een vaste dispersie van een farmaceutisch actief middel dat een lage oplosbaarheid in water heeft, in een vaste matrix van een in water oplosbaar polyalkyleenglycol als drager.
US4803081A (en) New pharmaceutical preparations with extended release
EP1474144B1 (en) Controlled release pharmaceutical dosage forms of a cholesteryl ester transfer protein inhibitor
US7235260B2 (en) Pharmaceutical compositions of a sparingly soluble glycogen phosphorylase inhibitor
MXPA06001506A (es) Formas de dosificacion de inhibidores de la proteina de transferencia de colesteril ester e inhibidores de la hmg-coa reductasa.
JP2006528985A (ja) １つ以上の界面改変剤でコーティングされた、抗癲癇剤または免疫抑制剤を含有する固体粒子
US20060193910A1 (en) Tablets with improved drug substance dispersibility
WO2007007182A2 (en) Solid and liquid dosage forms of an antiepileptic agent
WO2015019256A1 (en) Pharmaceutical composition of vilazodone and processes of preparation thereof
JP2008524291A (ja) 固体医薬組成物
KR890001501B1 (ko) 조절된 서방성을 지닌 활성제의 고형분산액 제조방벙
JP2935117B2 (ja) ナノスフェア製剤
CH670201A5 (en) Solid dispersions of water-insol. drugs - comprising coherent crystals of drug in water-soluble matrix
NZ233954A (en) Sustained release pharmaceutical composition comprising 4-(2,1,3-benzoxadiazol-4-yl)-1,4-dihydro-5-methoxycarbonyl-2,6-dimethyl-3-pyridine carboxylic acid isopropyl ester
JPS6110507A (ja) 新規遅効性製剤
MXPA00006574A (en) Method and composition of an oral preparation of itraconazole
AU2003201713A1 (en) Controlled release pharmaceutical dosage forms of a cholesteryl ester transfer protein inhibitor

Legal Events

Date Code Title Description
BA A request for search or an international-type search has been filed
BB A search report has been drawn up
BC A request for examination has been filed
CNR Transfer of rights (patent application after its laying open for public inspection)

Free format text: NOVARTIS AG

V4 Discontinued because of reaching the maximum lifetime of a patent

Effective date: 20050531